EMA Probes Injectable Iron Medicines for Bone Risks Edited by Zeel Mehta

https://www.medscape.com/viewarticle/ema-probes-injectable-iron-medicines-bone-risks-2026a1000x5x?src= Reports of severe hypophosphatemia linked to injectable iron medicines — including cases of osteomalacia after just one or two doses and in patients with no recognized risk factors — have prompted a European safety review. The European Medicines Agency’s Pharmacovigilance Risk Assessment Committee (PRAC) has launched the review across all injectable iron formulations, not only ferric carboxymaltose, amid concerns that current risk-minimization measures may not be sufficient.